This regulatory network was inferred from the input dataset. The miRNAs and mRNAs are
presented as round and rectangle nodes respectively. The numerical value popped up upon mouse over the gene node is the log2 transformed fold-change of the gene expression between the two groups. All of the nodes are clickable, and the detailed information of the miRNAs/mRNAs and related cancer pathway will be displayed in another window. The edges between nodes are supported by both interactions (predicted or experimentally verified) and correlations learnt from cancer dataset. The numerical value popped up upon mouse over the edge is the correlation beat value (effect size) between the two nodes. The experimental evidences of the edges reported in previous cancer studies are highlighted by red/orange color. All of these information can be accessed by the "mouse-over" action. This network shows a full map of the miRNA-mRNA regulation of the input gene list(s), and the hub miRNAs (with the high network degree/betweenness centrality) would be the potential cancer drivers or tumor suppressors. The full result table can be accessed in the "Regulations" tab.
"miRNACancerMAP" is also a network visualization tool for users to draw their regulatory network by personal customization. Users can set the complexity of the network by limiting the number of nodes or edges. And the color of the nodes can be defined by different categories of the mRNAs and miRNAs, such as Gene-Ontology, pathway, and expression status. Users can also select to use network degree or network betweenness centrality to define the node size. And edges can be black or colored by the correlation. Purple edge means negative correlation (mostly found between miRNA and mRNA), and blue edge means positive correlation (found in PPI or miRNA-miRNA sponge effect). We can also add the protein-protein interactions (PPI) into the network. This result will show the cluster of genes regulated by some specific miRNAs. Additionally, miRNA-miRNA edges can be added by the "miRNA sponge" button, presenting some clusters of miRNAs that have the interactions via sponge effect.
Num | microRNA | Gene | miRNA log2FC | miRNA pvalue | Gene log2FC | Gene pvalue | Interaction | Correlation beta | Correlation P-value | PMID | Reported in cancer studies |
---|---|---|---|---|---|---|---|---|---|---|---|
1 | hsa-miR-17-5p | AADAC | 0.7 | 2.0E-5 | -1.53 | 0 | MirTarget | -0.19 | 0.04679 | NA | |
2 | hsa-miR-17-5p | AAK1 | 0.7 | 2.0E-5 | 0.62 | 0 | TargetScan | -0.11 | 0.0001 | NA | |
3 | hsa-miR-17-5p | ABHD2 | 0.7 | 2.0E-5 | -1.2 | 0 | TargetScan; miRNATAP | -0.33 | 0 | NA | |
4 | hsa-miR-17-5p | ABHD5 | 0.7 | 2.0E-5 | -0.6 | 0 | MirTarget; TargetScan | -0.15 | 0 | NA | |
5 | hsa-miR-17-5p | ACBD5 | 0.7 | 2.0E-5 | -0.75 | 0 | TargetScan | -0.23 | 0 | NA | |
6 | hsa-miR-17-5p | ACER2 | 0.7 | 2.0E-5 | -1.22 | 0 | TargetScan | -0.41 | 0 | NA | |
7 | hsa-miR-17-5p | ACER3 | 0.7 | 2.0E-5 | 0.02 | 0.84604 | mirMAP | -0.1 | 0.00064 | NA | |
8 | hsa-miR-17-5p | ACOT2 | 0.7 | 2.0E-5 | -1.29 | 0 | miRNAWalker2 validate | -0.19 | 0.00011 | NA | |
9 | hsa-miR-17-5p | ACOX1 | 0.7 | 2.0E-5 | -1.16 | 0 | mirMAP | -0.22 | 0 | NA | |
10 | hsa-miR-17-5p | ACSL6 | 0.7 | 2.0E-5 | 0.39 | 0.26458 | mirMAP | -0.37 | 0.00035 | NA | |
11 | hsa-miR-17-5p | ACTR3C | 0.7 | 2.0E-5 | -0.99 | 0 | mirMAP | -0.25 | 0 | NA | |
12 | hsa-miR-17-5p | ADAM9 | 0.7 | 2.0E-5 | 0.47 | 0.00581 | TargetScan; miRNATAP | -0.2 | 8.0E-5 | NA | |
13 | hsa-miR-17-5p | ADAMTS5 | 0.7 | 2.0E-5 | -0.16 | 0.36499 | TargetScan | -0.11 | 0.03358 | NA | |
14 | hsa-miR-17-5p | ADAMTSL2 | 0.7 | 2.0E-5 | -2.68 | 0 | TargetScan | -0.28 | 0.00562 | NA | |
15 | hsa-miR-17-5p | ADARB1 | 0.7 | 2.0E-5 | -0.13 | 0.22208 | miRNAWalker2 validate; MirTarget | -0.13 | 7.0E-5 | NA | |
16 | hsa-miR-17-5p | ADCY1 | 0.7 | 2.0E-5 | -2.7 | 0 | mirMAP | -0.24 | 0.03129 | NA | |
17 | hsa-miR-17-5p | ADCY9 | 0.7 | 2.0E-5 | -0.11 | 0.30518 | mirMAP | -0.12 | 0.00011 | NA | |
18 | hsa-miR-17-5p | ADIPOR2 | 0.7 | 2.0E-5 | -0.68 | 0 | TargetScan | -0.13 | 8.0E-5 | NA | |
19 | hsa-miR-17-5p | ADRA1B | 0.7 | 2.0E-5 | -2.34 | 0 | TargetScan | -0.56 | 0 | NA | |
20 | hsa-miR-17-5p | AEN | 0.7 | 2.0E-5 | 0.28 | 0.01239 | MirTarget; TargetScan | -0.11 | 0.00144 | NA | |
21 | hsa-miR-17-5p | AFF1 | 0.7 | 2.0E-5 | -0.71 | 0 | TargetScan | -0.14 | 3.0E-5 | NA | |
22 | hsa-miR-17-5p | AFF4 | 0.7 | 2.0E-5 | -0.64 | 0 | TargetScan; miRNATAP | -0.14 | 0 | NA | |
23 | hsa-miR-17-5p | AGFG2 | 0.7 | 2.0E-5 | -0.02 | 0.87061 | TargetScan; miRNATAP | -0.11 | 0.00181 | NA | |
24 | hsa-miR-17-5p | AHRR | 0.7 | 2.0E-5 | 0.37 | 0.09373 | MirTarget; TargetScan | -0.14 | 0.03047 | NA | |
25 | hsa-miR-17-5p | AKAP11 | 0.7 | 2.0E-5 | -0.7 | 0 | MirTarget; TargetScan | -0.19 | 0 | NA | |
26 | hsa-miR-17-5p | AKAP13 | 0.7 | 2.0E-5 | -0.32 | 0.00142 | MirTarget; TargetScan; mirMAP; miRNATAP | -0.16 | 0 | NA | |
27 | hsa-miR-17-5p | AKAP9 | 0.7 | 2.0E-5 | -0.79 | 0 | TargetScan | -0.18 | 2.0E-5 | NA | |
28 | hsa-miR-17-5p | AKT3 | 0.7 | 2.0E-5 | -0.66 | 0.00047 | TargetScan; miRNATAP | -0.29 | 0 | NA | |
29 | hsa-miR-17-5p | AKTIP | 0.7 | 2.0E-5 | -0.37 | 0.00054 | MirTarget; TargetScan; miRNATAP | -0.28 | 0 | NA | |
30 | hsa-miR-17-5p | ANKFY1 | 0.7 | 2.0E-5 | -0.58 | 0 | MirTarget; TargetScan | -0.15 | 0 | NA | |
31 | hsa-miR-17-5p | ANKIB1 | 0.7 | 2.0E-5 | 0.07 | 0.50551 | TargetScan; miRNATAP | -0.12 | 4.0E-5 | NA | |
32 | hsa-miR-17-5p | ANKRD17 | 0.7 | 2.0E-5 | -0.34 | 0.00103 | TargetScan | -0.14 | 0 | NA | |
33 | hsa-miR-17-5p | ANKRD29 | 0.7 | 2.0E-5 | 1.13 | 4.0E-5 | MirTarget; TargetScan | -0.48 | 0 | NA | |
34 | hsa-miR-17-5p | ANKRD50 | 0.7 | 2.0E-5 | -0.25 | 0.04433 | MirTarget; TargetScan; miRNATAP | -0.22 | 0 | NA | |
35 | hsa-miR-17-5p | ANO6 | 0.7 | 2.0E-5 | -0.29 | 0.00464 | MirTarget; TargetScan; miRNATAP | -0.14 | 1.0E-5 | NA | |
36 | hsa-miR-17-5p | AP3S2 | 0.7 | 2.0E-5 | -0.33 | 4.0E-5 | mirMAP | -0.1 | 1.0E-5 | NA | |
37 | hsa-miR-17-5p | APBB2 | 0.7 | 2.0E-5 | -0.24 | 0.03085 | MirTarget; TargetScan; miRNATAP | -0.23 | 0 | NA | |
38 | hsa-miR-17-5p | APCDD1 | 0.7 | 2.0E-5 | -1.3 | 0.00043 | MirTarget; TargetScan | -0.27 | 0.01168 | NA | |
39 | hsa-miR-17-5p | AR | 0.7 | 2.0E-5 | -2.66 | 0 | mirMAP | -0.93 | 0 | 23095762 | miR 17 5p targets the p300/CBP associated factor and modulates androgen receptor transcriptional activity in cultured prostate cancer cells; Targeting of the 3'-untranslated region of PCAF mRNA by miR-17-5p caused translational suppression and RNA degradation and consequently modulation of AR transcriptional activity in PCa cells; Targeting of PCAF by miR-17-5p modulates AR transcriptional activity and cell growth in cultured PCa cells |
40 | hsa-miR-17-5p | ARAP2 | 0.7 | 2.0E-5 | -1.13 | 0 | MirTarget; TargetScan | -0.19 | 0.00017 | NA | |
41 | hsa-miR-17-5p | ARHGAP10 | 0.7 | 2.0E-5 | -1.87 | 0 | miRNAWalker2 validate | -0.37 | 0 | NA | |
42 | hsa-miR-17-5p | ARHGAP12 | 0.7 | 2.0E-5 | 0.04 | 0.72248 | TargetScan; miRNATAP | -0.1 | 0.00059 | NA | |
43 | hsa-miR-17-5p | ARHGAP23 | 0.7 | 2.0E-5 | -0.14 | 0.32985 | mirMAP | -0.19 | 1.0E-5 | NA | |
44 | hsa-miR-17-5p | ARHGAP24 | 0.7 | 2.0E-5 | -0.99 | 0 | MirTarget | -0.29 | 0 | NA | |
45 | hsa-miR-17-5p | ARHGAP31 | 0.7 | 2.0E-5 | -0.42 | 0.00347 | TargetScan | -0.25 | 0 | NA | |
46 | hsa-miR-17-5p | ARHGAP5 | 0.7 | 2.0E-5 | -0.39 | 8.0E-5 | miRNAWalker2 validate | -0.17 | 0 | NA | |
47 | hsa-miR-17-5p | ARHGEF10 | 0.7 | 2.0E-5 | 0.05 | 0.78887 | TargetScan | -0.27 | 0 | NA | |
48 | hsa-miR-17-5p | ARIH1 | 0.7 | 2.0E-5 | -0.13 | 0.06993 | miRNAWalker2 validate | -0.12 | 0 | NA | |
49 | hsa-miR-17-5p | ARL10 | 0.7 | 2.0E-5 | -0.42 | 0.01556 | mirMAP | -0.12 | 0.01623 | NA | |
50 | hsa-miR-17-5p | ARL13B | 0.7 | 2.0E-5 | -0.32 | 0.01196 | MirTarget | -0.13 | 0.00029 | NA | |
51 | hsa-miR-17-5p | ARSD | 0.7 | 2.0E-5 | -1.16 | 0 | mirMAP | -0.39 | 0 | NA | |
52 | hsa-miR-17-5p | ARSJ | 0.7 | 2.0E-5 | -1.41 | 0 | TargetScan | -0.5 | 0 | NA | |
53 | hsa-miR-17-5p | ASPA | 0.7 | 2.0E-5 | -2.88 | 0 | mirMAP | -0.3 | 0.00071 | NA | |
54 | hsa-miR-17-5p | ASXL2 | 0.7 | 2.0E-5 | -0.29 | 0.18051 | TargetScan | -0.24 | 0.00015 | NA | |
55 | hsa-miR-17-5p | ASXL3 | 0.7 | 2.0E-5 | -2.69 | 0 | TargetScan | -0.47 | 2.0E-5 | NA | |
56 | hsa-miR-17-5p | ATE1 | 0.7 | 2.0E-5 | -0.6 | 0.0009 | MirTarget; TargetScan | -0.17 | 0.00187 | NA | |
57 | hsa-miR-17-5p | ATF3 | 0.7 | 2.0E-5 | -1.88 | 0 | miRNAWalker2 validate | -0.29 | 0 | NA | |
58 | hsa-miR-17-5p | ATL3 | 0.7 | 2.0E-5 | 0.13 | 0.25255 | MirTarget; TargetScan; miRNATAP | -0.2 | 0 | NA | |
59 | hsa-miR-17-5p | ATOH8 | 0.7 | 2.0E-5 | -2.68 | 0 | TargetScan | -0.7 | 0 | NA | |
60 | hsa-miR-17-5p | ATP1A2 | 0.7 | 2.0E-5 | 0.51 | 0.11121 | MirTarget; TargetScan | -0.36 | 0.00013 | NA | |
61 | hsa-miR-17-5p | ATRX | 0.7 | 2.0E-5 | -0.07 | 0.48759 | miRNAWalker2 validate; mirMAP | -0.12 | 3.0E-5 | NA | |
62 | hsa-miR-17-5p | ATXN1L | 0.7 | 2.0E-5 | 0.09 | 0.38956 | TargetScan; miRNATAP | -0.17 | 0 | NA | |
63 | hsa-miR-17-5p | ATXN7L1 | 0.7 | 2.0E-5 | -0.24 | 0.06065 | TargetScan | -0.35 | 0 | NA | |
64 | hsa-miR-17-5p | BBX | 0.7 | 2.0E-5 | -0.07 | 0.54321 | MirTarget; TargetScan; miRNATAP | -0.18 | 0 | NA | |
65 | hsa-miR-17-5p | BCL2 | 0.7 | 2.0E-5 | -0.35 | 0.02497 | miRNAWalker2 validate; miRTarBase | -0.31 | 0 | 25435430 | Combined overexpression of miR-16 and miR-17 greatly reduced Beclin-1 and Bcl-2 expressions respectively; miR-17 overexpression reduced cytoprotective autophagy by targeting Beclin-1 whereas overexpression of miR-16 potentiated paclitaxel induced apoptotic cell death by inhibiting anti-apoptotic protein Bcl-2 |
66 | hsa-miR-17-5p | BHLHE41 | 0.7 | 2.0E-5 | -0.4 | 0.15906 | TargetScan; miRNATAP | -0.37 | 1.0E-5 | NA | |
67 | hsa-miR-17-5p | BMP2K | 0.7 | 2.0E-5 | -0.82 | 0 | TargetScan | -0.17 | 1.0E-5 | NA | |
68 | hsa-miR-17-5p | BMPR2 | 0.7 | 2.0E-5 | -0.74 | 0 | miRNAWalker2 validate; MirTarget; TargetScan; miRNATAP | -0.26 | 0 | NA | |
69 | hsa-miR-17-5p | BNC2 | 0.7 | 2.0E-5 | -0.39 | 0.08973 | TargetScan; miRNATAP | -0.34 | 0 | NA | |
70 | hsa-miR-17-5p | BNIP3L | 0.7 | 2.0E-5 | -0.67 | 0 | MirTarget; TargetScan | -0.19 | 0 | NA | |
71 | hsa-miR-17-5p | BTN3A1 | 0.7 | 2.0E-5 | 0.33 | 0.01478 | miRNAWalker2 validate | -0.28 | 0 | NA | |
72 | hsa-miR-17-5p | BVES | 0.7 | 2.0E-5 | -0.6 | 0.00365 | TargetScan | -0.2 | 0.00085 | NA | |
73 | hsa-miR-17-5p | C16orf52 | 0.7 | 2.0E-5 | -0.5 | 0 | TargetScan; miRNATAP | -0.24 | 0 | NA | |
74 | hsa-miR-17-5p | C16orf70 | 0.7 | 2.0E-5 | -0.77 | 0 | TargetScan | -0.14 | 5.0E-5 | NA | |
75 | hsa-miR-17-5p | C16orf72 | 0.7 | 2.0E-5 | -0.44 | 0 | TargetScan | -0.13 | 0 | NA | |
76 | hsa-miR-17-5p | C18orf25 | 0.7 | 2.0E-5 | -0.11 | 0.11389 | mirMAP | -0.11 | 0 | NA | |
77 | hsa-miR-17-5p | C2CD2 | 0.7 | 2.0E-5 | 0.04 | 0.76174 | MirTarget; TargetScan; miRNATAP | -0.17 | 0 | NA | |
78 | hsa-miR-17-5p | C2orf69 | 0.7 | 2.0E-5 | -0.19 | 0.04079 | TargetScan | -0.21 | 0 | NA | |
79 | hsa-miR-17-5p | C3orf70 | 0.7 | 2.0E-5 | 0.49 | 0.00136 | TargetScan | -0.1 | 0.0268 | NA | |
80 | hsa-miR-17-5p | CA5B | 0.7 | 2.0E-5 | 0.77 | 1.0E-5 | mirMAP | -0.17 | 0.00077 | NA | |
81 | hsa-miR-17-5p | CALD1 | 0.7 | 2.0E-5 | -0.53 | 0 | TargetScan; miRNATAP | -0.23 | 0 | NA | |
82 | hsa-miR-17-5p | CAMTA2 | 0.7 | 2.0E-5 | -0.35 | 8.0E-5 | MirTarget; TargetScan | -0.11 | 1.0E-5 | NA | |
83 | hsa-miR-17-5p | CASC4 | 0.7 | 2.0E-5 | -0.46 | 0 | MirTarget | -0.21 | 0 | NA | |
84 | hsa-miR-17-5p | CASK | 0.7 | 2.0E-5 | 0.43 | 0.00011 | mirMAP | -0.22 | 0 | NA | |
85 | hsa-miR-17-5p | CBX7 | 0.7 | 2.0E-5 | -0.08 | 0.52937 | mirMAP | -0.25 | 0 | NA | |
86 | hsa-miR-17-5p | CC2D1A | 0.7 | 2.0E-5 | 0.26 | 0.00869 | MirTarget; TargetScan; miRNATAP | -0.15 | 0 | NA | |
87 | hsa-miR-17-5p | CCBE1 | 0.7 | 2.0E-5 | -5.46 | 0 | mirMAP | -0.59 | 0 | NA | |
88 | hsa-miR-17-5p | CCDC103 | 0.7 | 2.0E-5 | -0.03 | 0.84263 | mirMAP | -0.15 | 0.00403 | NA | |
89 | hsa-miR-17-5p | CCDC25 | 0.7 | 2.0E-5 | -1.1 | 0 | TargetScan | -0.18 | 0 | NA | |
90 | hsa-miR-17-5p | CCND1 | 0.7 | 2.0E-5 | -0.9 | 1.0E-5 | miRNAWalker2 validate; MirTarget; TargetScan; miRNATAP | -0.34 | 0 | 26431674 | Bioinformatics Prediction and In Vitro Analysis Revealed That miR 17 Targets Cyclin D1 mRNA in Triple Negative Breast Cancer Cells; In this study using bioinformatic analyses miR-17 was selected as it targets the 3'UTR of CCND1 gene with the highest score; After lentiviral transduction of miR-17 to the target cells gene expression analysis showed decreased expression of CCND1 gene |
91 | hsa-miR-17-5p | CCND2 | 0.7 | 2.0E-5 | 0.36 | 0.03656 | miRNAWalker2 validate; miRTarBase; TargetScan; miRNATAP | -0.11 | 0.02358 | NA | |
92 | hsa-miR-17-5p | CD226 | 0.7 | 2.0E-5 | -2.15 | 0 | TargetScan | -0.19 | 0.0112 | NA | |
93 | hsa-miR-17-5p | CD274 | 0.7 | 2.0E-5 | -1.27 | 0 | MirTarget; TargetScan; miRNATAP | -0.44 | 0 | NA | |
94 | hsa-miR-17-5p | CD69 | 0.7 | 2.0E-5 | -1.75 | 0 | TargetScan; miRNATAP | -0.17 | 0.0246 | NA | |
95 | hsa-miR-17-5p | CDC37L1 | 0.7 | 2.0E-5 | -1.68 | 0 | MirTarget; TargetScan; miRNATAP | -0.38 | 0 | NA | |
96 | hsa-miR-17-5p | CDH19 | 0.7 | 2.0E-5 | -4.11 | 0 | TargetScan | -0.37 | 0.00314 | NA | |
97 | hsa-miR-17-5p | CDK6 | 0.7 | 2.0E-5 | -0.31 | 0.22057 | TargetScan; mirMAP | -0.33 | 0 | NA | |
98 | hsa-miR-17-5p | CDKN1A | 0.7 | 2.0E-5 | -0.77 | 6.0E-5 | miRNAWalker2 validate; miRTarBase; MirTarget; TargetScan; miRNATAP | -0.3 | 0 | 26482648; 24989082 | The low expressions of miR-17 and miR-92 families can maintain cisplatin resistance through the regulation of CDKN1A and RAD21;According to PicTar and Miranda algorithms which predicted CDKN1A p21 as a putative target of miR-17 a luciferase assay was performed and revealed that miR-17 directly targets the 3'-UTR of p21 mRNA |
99 | hsa-miR-17-5p | CELF2 | 0.7 | 2.0E-5 | -0.74 | 8.0E-5 | TargetScan | -0.18 | 0.00125 | NA | |
100 | hsa-miR-17-5p | CELSR2 | 0.7 | 2.0E-5 | 0.41 | 0.02717 | TargetScan; miRNATAP | -0.12 | 0.02326 | NA | |
101 | hsa-miR-17-5p | CEP120 | 0.7 | 2.0E-5 | -0.39 | 2.0E-5 | MirTarget; TargetScan; miRNATAP | -0.11 | 2.0E-5 | NA | |
102 | hsa-miR-17-5p | CEP97 | 0.7 | 2.0E-5 | 0.29 | 0.07184 | MirTarget; TargetScan; miRNATAP | -0.13 | 0.00468 | NA | |
103 | hsa-miR-17-5p | CFL2 | 0.7 | 2.0E-5 | -1.18 | 0 | MirTarget; TargetScan; miRNATAP | -0.2 | 0 | NA | |
104 | hsa-miR-17-5p | CHD9 | 0.7 | 2.0E-5 | -0.51 | 3.0E-5 | MirTarget; TargetScan; miRNATAP | -0.29 | 0 | NA | |
105 | hsa-miR-17-5p | CHIC1 | 0.7 | 2.0E-5 | -1.1 | 1.0E-5 | TargetScan | -0.24 | 0.00094 | NA | |
106 | hsa-miR-17-5p | CHST7 | 0.7 | 2.0E-5 | -1.56 | 0 | TargetScan | -0.2 | 0.00092 | NA | |
107 | hsa-miR-17-5p | CHTF8 | 0.7 | 2.0E-5 | -0.4 | 0 | miRNAWalker2 validate | -0.13 | 0 | NA | |
108 | hsa-miR-17-5p | CIITA | 0.7 | 2.0E-5 | 0.27 | 0.18011 | mirMAP | -0.16 | 0.00664 | NA | |
109 | hsa-miR-17-5p | CLIC6 | 0.7 | 2.0E-5 | -3.64 | 0 | mirMAP | -0.66 | 0 | NA | |
110 | hsa-miR-17-5p | CLIP4 | 0.7 | 2.0E-5 | -0.22 | 0.43954 | MirTarget; TargetScan | -0.3 | 0.00045 | NA | |
111 | hsa-miR-17-5p | CLOCK | 0.7 | 2.0E-5 | -0.53 | 0.00745 | MirTarget; TargetScan | -0.32 | 0 | NA | |
112 | hsa-miR-17-5p | CLUAP1 | 0.7 | 2.0E-5 | 0.14 | 0.12444 | mirMAP | -0.12 | 0 | NA | |
113 | hsa-miR-17-5p | CMKLR1 | 0.7 | 2.0E-5 | -0.79 | 1.0E-5 | TargetScan | -0.17 | 0.001 | NA | |
114 | hsa-miR-17-5p | CMPK1 | 0.7 | 2.0E-5 | -0.68 | 0 | MirTarget; TargetScan; miRNATAP | -0.16 | 0 | NA | |
115 | hsa-miR-17-5p | CNDP1 | 0.7 | 2.0E-5 | -6.39 | 0 | mirMAP | -0.84 | 0 | NA | |
116 | hsa-miR-17-5p | CNN1 | 0.7 | 2.0E-5 | 0.41 | 0.09282 | TargetScan | -0.28 | 6.0E-5 | NA | |
117 | hsa-miR-17-5p | CNOT6L | 0.7 | 2.0E-5 | -0.53 | 0 | TargetScan | -0.15 | 0 | NA | |
118 | hsa-miR-17-5p | CNTNAP3 | 0.7 | 2.0E-5 | 0.11 | 0.74285 | MirTarget | -0.46 | 0 | NA | |
119 | hsa-miR-17-5p | COL4A3 | 0.7 | 2.0E-5 | -0.93 | 0.00622 | MirTarget; TargetScan; miRNATAP | -0.29 | 0.00372 | NA | |
120 | hsa-miR-17-5p | CPEB3 | 0.7 | 2.0E-5 | -2.74 | 0 | TargetScan; miRNATAP | -0.53 | 0 | NA | |
121 | hsa-miR-17-5p | CPEB4 | 0.7 | 2.0E-5 | -1.06 | 0 | mirMAP | -0.27 | 0 | NA | |
122 | hsa-miR-17-5p | CREB5 | 0.7 | 2.0E-5 | 0 | 0.99313 | MirTarget; TargetScan; miRNATAP | -0.13 | 0.02492 | NA | |
123 | hsa-miR-17-5p | CRIM1 | 0.7 | 2.0E-5 | -0.43 | 0.03963 | MirTarget; TargetScan; miRNATAP | -0.5 | 0 | NA | |
124 | hsa-miR-17-5p | CRK | 0.7 | 2.0E-5 | -0.66 | 0 | MirTarget; TargetScan; miRNATAP | -0.12 | 9.0E-5 | NA | |
125 | hsa-miR-17-5p | CRY2 | 0.7 | 2.0E-5 | -0.23 | 0.06667 | MirTarget; TargetScan; miRNATAP | -0.18 | 0 | NA | |
126 | hsa-miR-17-5p | CRYBG3 | 0.7 | 2.0E-5 | -0.7 | 0.01151 | MirTarget; TargetScan; miRNATAP | -0.52 | 0 | NA | |
127 | hsa-miR-17-5p | CSF1 | 0.7 | 2.0E-5 | -0.59 | 0.00153 | TargetScan; miRNATAP | -0.24 | 1.0E-5 | NA | |
128 | hsa-miR-17-5p | CSGALNACT1 | 0.7 | 2.0E-5 | 0.19 | 0.22912 | MirTarget; TargetScan | -0.22 | 0 | NA | |
129 | hsa-miR-17-5p | CXCL14 | 0.7 | 2.0E-5 | -6.87 | 0 | TargetScan | -0.75 | 0 | NA | |
130 | hsa-miR-17-5p | CXCL6 | 0.7 | 2.0E-5 | -3.43 | 0 | MirTarget | -0.69 | 5.0E-5 | NA | |
131 | hsa-miR-17-5p | CXorf23 | 0.7 | 2.0E-5 | 0.43 | 1.0E-5 | mirMAP | -0.11 | 6.0E-5 | NA | |
132 | hsa-miR-17-5p | CXorf56 | 0.7 | 2.0E-5 | -0.01 | 0.97138 | TargetScan | -0.2 | 3.0E-5 | NA | |
133 | hsa-miR-17-5p | CYBRD1 | 0.7 | 2.0E-5 | -1.29 | 0 | MirTarget; TargetScan | -0.37 | 0 | NA | |
134 | hsa-miR-17-5p | CYP2U1 | 0.7 | 2.0E-5 | -1.02 | 0 | MirTarget; TargetScan | -0.41 | 0 | NA | |
135 | hsa-miR-17-5p | DAZAP2 | 0.7 | 2.0E-5 | -0.39 | 0 | MirTarget; TargetScan; miRNATAP | -0.12 | 0 | NA | |
136 | hsa-miR-17-5p | DCAF8 | 0.7 | 2.0E-5 | -0.03 | 0.75166 | TargetScan; miRNATAP | -0.12 | 0 | NA | |
137 | hsa-miR-17-5p | DCUN1D3 | 0.7 | 2.0E-5 | -1.25 | 0 | MirTarget; TargetScan | -0.17 | 0 | NA | |
138 | hsa-miR-17-5p | DGKE | 0.7 | 2.0E-5 | -0.86 | 0 | MirTarget | -0.25 | 1.0E-5 | NA | |
139 | hsa-miR-17-5p | DIP2C | 0.7 | 2.0E-5 | -0.78 | 5.0E-5 | TargetScan | -0.3 | 0 | NA | |
140 | hsa-miR-17-5p | DIRC2 | 0.7 | 2.0E-5 | -0.06 | 0.49043 | MirTarget; TargetScan; miRNATAP | -0.24 | 0 | NA | |
141 | hsa-miR-17-5p | DIXDC1 | 0.7 | 2.0E-5 | -1.03 | 0 | mirMAP | -0.3 | 0 | NA | |
142 | hsa-miR-17-5p | DLG2 | 0.7 | 2.0E-5 | -1.95 | 0 | mirMAP | -0.41 | 0 | NA | |
143 | hsa-miR-17-5p | DNAJB9 | 0.7 | 2.0E-5 | -0.63 | 0 | TargetScan; miRNATAP | -0.24 | 0 | NA | |
144 | hsa-miR-17-5p | DNAJC15 | 0.7 | 2.0E-5 | -0.71 | 0 | TargetScan | -0.15 | 0.00097 | NA | |
145 | hsa-miR-17-5p | DNAJC27 | 0.7 | 2.0E-5 | -0.35 | 0.00026 | miRNAWalker2 validate; miRTarBase; MirTarget; TargetScan; miRNATAP | -0.18 | 0 | NA | |
146 | hsa-miR-17-5p | DNAL1 | 0.7 | 2.0E-5 | -0.09 | 0.30099 | TargetScan | -0.14 | 0 | NA | |
147 | hsa-miR-17-5p | DNMBP | 0.7 | 2.0E-5 | -0.66 | 0 | miRNAWalker2 validate | -0.13 | 0.00031 | NA | |
148 | hsa-miR-17-5p | DOCK4 | 0.7 | 2.0E-5 | -0.2 | 0.07305 | MirTarget; TargetScan | -0.14 | 1.0E-5 | NA | |
149 | hsa-miR-17-5p | DPF3 | 0.7 | 2.0E-5 | -2.59 | 0 | TargetScan | -0.51 | 0 | NA | |
150 | hsa-miR-17-5p | DPP8 | 0.7 | 2.0E-5 | -0.27 | 0.06918 | mirMAP | -0.13 | 0.00459 | NA |
Num | GO | Overlap | Size | P Value | Adj. P Value |
---|---|---|---|---|---|
1 | TISSUE DEVELOPMENT | 116 | 1518 | 1.958e-15 | 9.112e-12 |
2 | POSITIVE REGULATION OF CATALYTIC ACTIVITY | 110 | 1518 | 4.046e-13 | 9.412e-10 |
3 | CARDIOVASCULAR SYSTEM DEVELOPMENT | 70 | 788 | 1.554e-12 | 1.808e-09 |
4 | CIRCULATORY SYSTEM DEVELOPMENT | 70 | 788 | 1.554e-12 | 1.808e-09 |
5 | POSITIVE REGULATION OF MOLECULAR FUNCTION | 120 | 1791 | 5.992e-12 | 5.576e-09 |
6 | REGULATION OF TRANSCRIPTION FROM RNA POLYMERASE II PROMOTER | 118 | 1784 | 2.144e-11 | 1.663e-08 |
7 | INTRACELLULAR SIGNAL TRANSDUCTION | 106 | 1572 | 8.954e-11 | 5.208e-08 |
8 | REGULATION OF SMALL GTPASE MEDIATED SIGNAL TRANSDUCTION | 35 | 278 | 8.699e-11 | 5.208e-08 |
9 | NEGATIVE REGULATION OF TRANSCRIPTION FROM RNA POLYMERASE II PROMOTER | 62 | 740 | 3.476e-10 | 1.797e-07 |
10 | HEART DEVELOPMENT | 46 | 466 | 4.317e-10 | 2.009e-07 |
11 | ORGAN MORPHOGENESIS | 67 | 841 | 5.478e-10 | 2.317e-07 |
12 | EPITHELIUM DEVELOPMENT | 72 | 945 | 8.473e-10 | 3.285e-07 |
13 | ENZYME LINKED RECEPTOR PROTEIN SIGNALING PATHWAY | 58 | 689 | 1.115e-09 | 3.706e-07 |
14 | CELL MORPHOGENESIS INVOLVED IN DIFFERENTIATION | 48 | 513 | 1.08e-09 | 3.706e-07 |
15 | TISSUE MORPHOGENESIS | 49 | 533 | 1.303e-09 | 4.042e-07 |
16 | TUBE DEVELOPMENT | 50 | 552 | 1.455e-09 | 4.232e-07 |
17 | REGULATION OF CELL DIFFERENTIATION | 98 | 1492 | 2.062e-09 | 5.644e-07 |
18 | CELL DEVELOPMENT | 94 | 1426 | 3.863e-09 | 9.921e-07 |
19 | REGULATION OF PHOSPHORUS METABOLIC PROCESS | 103 | 1618 | 4.051e-09 | 9.921e-07 |
20 | VASCULATURE DEVELOPMENT | 44 | 469 | 5.018e-09 | 1.167e-06 |
21 | POSITIVE REGULATION OF PHOSPHATE METABOLIC PROCESS | 74 | 1036 | 7.981e-09 | 1.688e-06 |
22 | POSITIVE REGULATION OF PHOSPHORUS METABOLIC PROCESS | 74 | 1036 | 7.981e-09 | 1.688e-06 |
23 | POSITIVE REGULATION OF PROTEIN METABOLIC PROCESS | 96 | 1492 | 8.733e-09 | 1.767e-06 |
24 | REGULATION OF MULTICELLULAR ORGANISMAL DEVELOPMENT | 104 | 1672 | 1.145e-08 | 2.22e-06 |
25 | MUSCLE TISSUE DEVELOPMENT | 31 | 275 | 1.516e-08 | 2.822e-06 |
26 | NEGATIVE REGULATION OF GENE EXPRESSION | 95 | 1493 | 1.823e-08 | 3.262e-06 |
27 | REGULATION OF INTRACELLULAR SIGNAL TRANSDUCTION | 102 | 1656 | 2.669e-08 | 4.436e-06 |
28 | REGULATION OF CELLULAR COMPONENT MOVEMENT | 59 | 771 | 2.67e-08 | 4.436e-06 |
29 | POSITIVE REGULATION OF LOCOMOTION | 39 | 420 | 4.996e-08 | 8.016e-06 |
30 | REGULATION OF GTPASE ACTIVITY | 53 | 673 | 5.564e-08 | 8.629e-06 |
31 | POSITIVE REGULATION OF GENE EXPRESSION | 104 | 1733 | 7.136e-08 | 1.038e-05 |
32 | REGULATION OF PROTEIN MODIFICATION PROCESS | 103 | 1710 | 6.941e-08 | 1.038e-05 |
33 | POSITIVE REGULATION OF PROTEIN MODIFICATION PROCESS | 76 | 1135 | 7.459e-08 | 1.052e-05 |
34 | REGULATION OF KINASE ACTIVITY | 58 | 776 | 7.953e-08 | 1.088e-05 |
35 | REGULATION OF HYDROLASE ACTIVITY | 85 | 1327 | 8.433e-08 | 1.121e-05 |
36 | SKELETAL SYSTEM DEVELOPMENT | 40 | 455 | 1.472e-07 | 1.86e-05 |
37 | CELLULAR RESPONSE TO ORGANIC SUBSTANCE | 108 | 1848 | 1.479e-07 | 1.86e-05 |
38 | POSITIVE REGULATION OF BIOSYNTHETIC PROCESS | 106 | 1805 | 1.55e-07 | 1.898e-05 |
39 | CELLULAR COMPONENT MORPHOGENESIS | 63 | 900 | 2.281e-07 | 2.721e-05 |
40 | POSITIVE REGULATION OF KINASE ACTIVITY | 41 | 482 | 2.492e-07 | 2.854e-05 |
41 | POSITIVE REGULATION OF TRANSCRIPTION FROM RNA POLYMERASE II PROMOTER | 68 | 1004 | 2.515e-07 | 2.854e-05 |
42 | POSITIVE REGULATION OF HYDROLASE ACTIVITY | 63 | 905 | 2.769e-07 | 2.996e-05 |
43 | RESPONSE TO ENDOGENOUS STIMULUS | 89 | 1450 | 2.711e-07 | 2.996e-05 |
44 | NEGATIVE REGULATION OF NITROGEN COMPOUND METABOLIC PROCESS | 92 | 1517 | 2.845e-07 | 3.009e-05 |
45 | CELLULAR RESPONSE TO ENDOGENOUS STIMULUS | 68 | 1008 | 2.91e-07 | 3.009e-05 |
46 | MUSCLE STRUCTURE DEVELOPMENT | 38 | 432 | 2.977e-07 | 3.012e-05 |
47 | BLOOD VESSEL MORPHOGENESIS | 34 | 364 | 3.149e-07 | 3.117e-05 |
48 | NEURON PROJECTION MORPHOGENESIS | 36 | 402 | 3.973e-07 | 3.852e-05 |
49 | NEGATIVE REGULATION OF CELL PROLIFERATION | 49 | 643 | 4.759e-07 | 4.52e-05 |
50 | REGULATION OF TRANSFERASE ACTIVITY | 64 | 946 | 6.021e-07 | 5.603e-05 |
51 | POSITIVE REGULATION OF TRANSFERASE ACTIVITY | 47 | 616 | 7.913e-07 | 7.22e-05 |
52 | ANATOMICAL STRUCTURE FORMATION INVOLVED IN MORPHOGENESIS | 64 | 957 | 8.954e-07 | 8.012e-05 |
53 | MOVEMENT OF CELL OR SUBCELLULAR COMPONENT | 79 | 1275 | 9.459e-07 | 8.304e-05 |
54 | MORPHOGENESIS OF AN EPITHELIUM | 35 | 400 | 9.886e-07 | 8.518e-05 |
55 | CELL MORPHOGENESIS INVOLVED IN NEURON DIFFERENTIATION | 33 | 368 | 1.172e-06 | 9.809e-05 |
56 | TRANSMEMBRANE RECEPTOR PROTEIN SERINE THREONINE KINASE SIGNALING PATHWAY | 22 | 190 | 1.181e-06 | 9.809e-05 |
57 | NEGATIVE REGULATION OF CELL COMMUNICATION | 74 | 1192 | 2.004e-06 | 0.0001636 |
58 | NEGATIVE REGULATION OF MULTICELLULAR ORGANISMAL PROCESS | 64 | 983 | 2.206e-06 | 0.000177 |
59 | REGULATION OF CELLULAR RESPONSE TO GROWTH FACTOR STIMULUS | 24 | 229 | 2.363e-06 | 0.0001863 |
60 | REGULATION OF RAS PROTEIN SIGNAL TRANSDUCTION | 21 | 184 | 2.596e-06 | 0.0002013 |
61 | EPITHELIAL CELL DEVELOPMENT | 21 | 186 | 3.089e-06 | 0.0002356 |
62 | HEAD DEVELOPMENT | 50 | 709 | 3.423e-06 | 0.0002569 |
63 | POSITIVE REGULATION OF RESPONSE TO STIMULUS | 106 | 1929 | 3.571e-06 | 0.0002596 |
64 | POSITIVE REGULATION OF EPITHELIAL CELL MIGRATION | 15 | 103 | 3.534e-06 | 0.0002596 |
65 | TRANSITION METAL ION HOMEOSTASIS | 15 | 106 | 5.086e-06 | 0.0003585 |
66 | TUBE MORPHOGENESIS | 29 | 323 | 5.052e-06 | 0.0003585 |
67 | NEUROGENESIS | 82 | 1402 | 5.47e-06 | 0.0003799 |
68 | NEURON PROJECTION DEVELOPMENT | 41 | 545 | 5.682e-06 | 0.0003888 |
69 | CENTRAL NERVOUS SYSTEM NEURON DEVELOPMENT | 12 | 70 | 5.962e-06 | 0.000402 |
70 | REGULATION OF CELL PROLIFERATION | 86 | 1496 | 6.185e-06 | 0.0004112 |
71 | TELENCEPHALON DEVELOPMENT | 23 | 228 | 7.239e-06 | 0.0004744 |
72 | POSITIVE REGULATION OF INTRACELLULAR SIGNAL TRANSDUCTION | 57 | 876 | 8.242e-06 | 0.0005327 |
73 | LOCOMOTION | 68 | 1114 | 9.363e-06 | 0.0005968 |
74 | UROGENITAL SYSTEM DEVELOPMENT | 27 | 299 | 9.569e-06 | 0.0006017 |
75 | CARDIAC MUSCLE TISSUE DEVELOPMENT | 17 | 140 | 1.009e-05 | 0.0006259 |
76 | NEGATIVE REGULATION OF RESPONSE TO STIMULUS | 79 | 1360 | 1.055e-05 | 0.0006461 |
77 | BONE DEVELOPMENT | 18 | 156 | 1.143e-05 | 0.0006759 |
78 | OSSIFICATION | 24 | 251 | 1.148e-05 | 0.0006759 |
79 | POSITIVE REGULATION OF DEVELOPMENTAL PROCESS | 69 | 1142 | 1.124e-05 | 0.0006759 |
80 | MUSCLE CELL DIFFERENTIATION | 23 | 237 | 1.367e-05 | 0.000795 |
81 | CENTRAL NERVOUS SYSTEM DEVELOPMENT | 56 | 872 | 1.445e-05 | 0.0008303 |
82 | CARDIAC CHAMBER DEVELOPMENT | 17 | 144 | 1.47e-05 | 0.0008339 |
83 | CHEMICAL HOMEOSTASIS | 56 | 874 | 1.543e-05 | 0.000865 |
84 | REGULATION OF CIRCADIAN RHYTHM | 14 | 103 | 1.673e-05 | 0.0009266 |
85 | MESONEPHROS DEVELOPMENT | 13 | 90 | 1.715e-05 | 0.0009387 |
86 | VENTRICULAR SEPTUM DEVELOPMENT | 10 | 54 | 1.758e-05 | 0.0009511 |
87 | HOMEOSTATIC PROCESS | 77 | 1337 | 1.854e-05 | 0.0009918 |
88 | PROTEIN PHOSPHORYLATION | 59 | 944 | 1.894e-05 | 0.001002 |
89 | REGULATION OF OSSIFICATION | 19 | 178 | 2.017e-05 | 0.001054 |
90 | CELLULAR RESPONSE TO OXYGEN CONTAINING COMPOUND | 52 | 799 | 2.059e-05 | 0.001064 |
91 | POSITIVE REGULATION OF ENDOTHELIAL CELL MIGRATION | 11 | 67 | 2.222e-05 | 0.001124 |
92 | NEGATIVE REGULATION OF DEVELOPMENTAL PROCESS | 52 | 801 | 2.202e-05 | 0.001124 |
93 | HEART MORPHOGENESIS | 21 | 212 | 2.357e-05 | 0.001179 |
94 | NEGATIVE REGULATION OF CELLULAR RESPONSE TO GROWTH FACTOR STIMULUS | 15 | 121 | 2.589e-05 | 0.001282 |
95 | CELLULAR RESPONSE TO EXTERNAL STIMULUS | 24 | 264 | 2.648e-05 | 0.001297 |
96 | EMBRYO DEVELOPMENT | 56 | 894 | 2.914e-05 | 0.001412 |
97 | NEURON DIFFERENTIATION | 55 | 874 | 3.03e-05 | 0.001454 |
98 | FOREBRAIN DEVELOPMENT | 29 | 357 | 3.348e-05 | 0.001567 |
99 | REGULATION OF PROTEIN SERINE THREONINE KINASE ACTIVITY | 35 | 470 | 3.368e-05 | 0.001567 |
100 | CENTRAL NERVOUS SYSTEM NEURON AXONOGENESIS | 7 | 27 | 3.321e-05 | 0.001567 |
101 | CELL PROJECTION ORGANIZATION | 56 | 902 | 3.726e-05 | 0.001717 |
102 | BIOLOGICAL ADHESION | 62 | 1032 | 3.774e-05 | 0.001722 |
103 | KIDNEY EPITHELIUM DEVELOPMENT | 15 | 125 | 3.812e-05 | 0.001722 |
104 | GLAND MORPHOGENESIS | 13 | 97 | 3.873e-05 | 0.001733 |
105 | EPITHELIAL CELL DIFFERENTIATION | 36 | 495 | 4.282e-05 | 0.001897 |
106 | CARDIAC SEPTUM DEVELOPMENT | 12 | 85 | 4.534e-05 | 0.001935 |
107 | POSITIVE REGULATION OF CELL COMMUNICATION | 84 | 1532 | 4.469e-05 | 0.001935 |
108 | POSITIVE REGULATION OF MULTICELLULAR ORGANISMAL PROCESS | 78 | 1395 | 4.477e-05 | 0.001935 |
109 | POSITIVE REGULATION OF CELL DIFFERENTIATION | 52 | 823 | 4.502e-05 | 0.001935 |
110 | TRANSMEMBRANE RECEPTOR PROTEIN TYROSINE KINASE SIGNALING PATHWAY | 36 | 498 | 4.851e-05 | 0.002052 |
111 | EMBRYONIC MORPHOGENESIS | 38 | 539 | 5.162e-05 | 0.002164 |
112 | RESPONSE TO HORMONE | 55 | 893 | 5.421e-05 | 0.002252 |
113 | RESPONSE TO OXYGEN CONTAINING COMPOUND | 77 | 1381 | 5.514e-05 | 0.00227 |
114 | VESICLE CYTOSKELETAL TRAFFICKING | 8 | 39 | 5.677e-05 | 0.002297 |
115 | TRABECULA MORPHOGENESIS | 8 | 39 | 5.677e-05 | 0.002297 |
116 | PROTEIN POLYUBIQUITINATION | 22 | 243 | 6.03e-05 | 0.002419 |
117 | CELLULAR RESPONSE TO ORGANIC CYCLIC COMPOUND | 34 | 465 | 6.249e-05 | 0.002485 |
118 | NEURON DEVELOPMENT | 45 | 687 | 6.383e-05 | 0.002517 |
119 | REGULATION OF HOMEOSTATIC PROCESS | 33 | 447 | 6.635e-05 | 0.002594 |
120 | REGULATION OF OSTEOCLAST DIFFERENTIATION | 10 | 63 | 7.04e-05 | 0.002713 |
121 | CELLULAR RESPONSE TO ABIOTIC STIMULUS | 23 | 263 | 7.055e-05 | 0.002713 |
122 | CYTOSKELETON ORGANIZATION | 52 | 838 | 7.167e-05 | 0.002733 |
123 | PROTEIN UBIQUITINATION | 42 | 629 | 7.291e-05 | 0.002736 |
124 | REGULATION OF CELL ADHESION | 42 | 629 | 7.291e-05 | 0.002736 |
125 | PHOSPHATE CONTAINING COMPOUND METABOLIC PROCESS | 102 | 1977 | 7.384e-05 | 0.002748 |
126 | CARDIAC CHAMBER MORPHOGENESIS | 13 | 104 | 8.096e-05 | 0.002966 |
127 | ACTIVATION OF MAPKK ACTIVITY | 9 | 52 | 8.058e-05 | 0.002966 |
128 | CELL PART MORPHOGENESIS | 42 | 633 | 8.394e-05 | 0.003028 |
129 | REGULATION OF BMP SIGNALING PATHWAY | 11 | 77 | 8.372e-05 | 0.003028 |
130 | PROTEIN UBIQUITINATION INVOLVED IN UBIQUITIN DEPENDENT PROTEIN CATABOLIC PROCESS | 15 | 134 | 8.563e-05 | 0.003042 |
131 | CELLULAR RESPONSE TO HORMONE STIMULUS | 38 | 552 | 8.522e-05 | 0.003042 |
132 | RESPONSE TO EXTERNAL STIMULUS | 95 | 1821 | 8.986e-05 | 0.003167 |
133 | CENTRAL NERVOUS SYSTEM PROJECTION NEURON AXONOGENESIS | 6 | 22 | 9.052e-05 | 0.003167 |
134 | REGULATION OF ANATOMICAL STRUCTURE MORPHOGENESIS | 60 | 1021 | 9.343e-05 | 0.003244 |
135 | CARDIAC VENTRICLE DEVELOPMENT | 13 | 106 | 9.869e-05 | 0.003402 |
136 | REGULATION OF VASOCONSTRICTION | 10 | 66 | 0.0001056 | 0.003599 |
137 | INTRACELLULAR RECEPTOR SIGNALING PATHWAY | 17 | 168 | 0.000106 | 0.003599 |
138 | PALLIUM DEVELOPMENT | 16 | 153 | 0.0001139 | 0.00384 |
139 | VENOUS BLOOD VESSEL DEVELOPMENT | 5 | 15 | 0.0001249 | 0.004182 |
140 | RESPONSE TO NITROGEN COMPOUND | 52 | 859 | 0.0001334 | 0.004433 |
141 | ORGAN GROWTH | 10 | 68 | 0.0001365 | 0.004505 |
142 | EMBRYONIC ORGAN DEVELOPMENT | 30 | 406 | 0.0001383 | 0.004533 |
143 | REGULATION OF CELL DEATH | 79 | 1472 | 0.000153 | 0.004979 |
144 | IRON ION HOMEOSTASIS | 10 | 69 | 0.0001547 | 0.004997 |
145 | REGULATION OF TRANSMEMBRANE RECEPTOR PROTEIN SERINE THREONINE KINASE SIGNALING PATHWAY | 19 | 207 | 0.0001571 | 0.005043 |
146 | REGULATION OF TRIGLYCERIDE METABOLIC PROCESS | 7 | 34 | 0.000162 | 0.005094 |
147 | POSITIVE REGULATION OF RESPONSE TO EXTERNAL STIMULUS | 24 | 296 | 0.0001603 | 0.005094 |
148 | SMALL GTPASE MEDIATED SIGNAL TRANSDUCTION | 27 | 352 | 0.000161 | 0.005094 |
149 | ACTIN FILAMENT BASED PROCESS | 32 | 450 | 0.0001697 | 0.0053 |
150 | ACTIVATION OF PROTEIN KINASE ACTIVITY | 23 | 279 | 0.0001709 | 0.005303 |
151 | REGULATION OF JNK CASCADE | 16 | 159 | 0.0001787 | 0.005507 |
152 | PHOSPHORYLATION | 68 | 1228 | 0.0001867 | 0.005716 |
153 | DEVELOPMENTAL MATURATION | 18 | 193 | 0.0001901 | 0.005783 |
154 | GLAND DEVELOPMENT | 29 | 395 | 0.0001982 | 0.005989 |
155 | CONNECTIVE TISSUE DEVELOPMENT | 18 | 194 | 0.0002028 | 0.006088 |
156 | TRANSCRIPTION FROM RNA POLYMERASE II PROMOTER | 45 | 724 | 0.0002106 | 0.006283 |
157 | RESPONSE TO STEROID HORMONE | 34 | 497 | 0.000223 | 0.006608 |
158 | CELL MOTILITY | 50 | 835 | 0.0002317 | 0.00678 |
159 | LOCALIZATION OF CELL | 50 | 835 | 0.0002317 | 0.00678 |
160 | POSITIVE REGULATION OF CYCLIN DEPENDENT PROTEIN KINASE ACTIVITY | 7 | 36 | 0.0002364 | 0.006874 |
161 | CARTILAGE DEVELOPMENT | 15 | 147 | 0.0002419 | 0.006926 |
162 | MAMMARY GLAND ALVEOLUS DEVELOPMENT | 5 | 17 | 0.0002426 | 0.006926 |
163 | MAMMARY GLAND LOBULE DEVELOPMENT | 5 | 17 | 0.0002426 | 0.006926 |
164 | ENTRAINMENT OF CIRCADIAN CLOCK | 6 | 26 | 0.0002474 | 0.006935 |
165 | CYTOSKELETON DEPENDENT INTRACELLULAR TRANSPORT | 13 | 116 | 0.0002467 | 0.006935 |
166 | POSITIVE REGULATION OF VASCULAR ENDOTHELIAL GROWTH FACTOR PRODUCTION | 6 | 26 | 0.0002474 | 0.006935 |
167 | ORGANELLE TRANSPORT ALONG MICROTUBULE | 9 | 60 | 0.0002514 | 0.007005 |
168 | DIGESTIVE SYSTEM DEVELOPMENT | 15 | 148 | 0.0002606 | 0.007217 |
169 | NEGATIVE REGULATION OF TRANSMEMBRANE RECEPTOR PROTEIN SERINE THREONINE KINASE SIGNALING PATHWAY | 12 | 102 | 0.0002689 | 0.007403 |
170 | CARDIAC MUSCLE CELL DIFFERENTIATION | 10 | 74 | 0.0002787 | 0.007627 |
171 | SIGNAL TRANSDUCTION BY PROTEIN PHOSPHORYLATION | 29 | 404 | 0.0002889 | 0.007862 |
172 | REGULATION OF EPITHELIAL CELL MIGRATION | 16 | 166 | 0.0002929 | 0.007878 |
173 | CENTRAL NERVOUS SYSTEM NEURON DIFFERENTIATION | 16 | 166 | 0.0002929 | 0.007878 |
174 | CELLULAR RESPONSE TO NITROGEN COMPOUND | 34 | 505 | 0.0002991 | 0.007998 |
175 | CELLULAR RESPONSE TO STEROID HORMONE STIMULUS | 19 | 218 | 0.0003056 | 0.008086 |
176 | NEGATIVE REGULATION OF CELL DIFFERENTIATION | 39 | 609 | 0.0003059 | 0.008086 |
177 | SKELETAL SYSTEM MORPHOGENESIS | 18 | 201 | 0.0003139 | 0.008253 |
178 | RESPONSE TO ABIOTIC STIMULUS | 58 | 1024 | 0.0003176 | 0.008301 |
179 | REGULATION OF SYSTEM PROCESS | 34 | 507 | 0.0003214 | 0.008355 |
180 | SMOOTH MUSCLE TISSUE DEVELOPMENT | 5 | 18 | 0.0003262 | 0.008385 |
181 | CENTROSOME LOCALIZATION | 5 | 18 | 0.0003262 | 0.008385 |
182 | ENDOTHELIUM DEVELOPMENT | 11 | 90 | 0.0003435 | 0.008783 |
183 | INTRINSIC APOPTOTIC SIGNALING PATHWAY | 15 | 152 | 0.0003481 | 0.008802 |
184 | ANGIOGENESIS | 23 | 293 | 0.0003467 | 0.008802 |
185 | POSITIVE REGULATION OF MAPK CASCADE | 32 | 470 | 0.0003672 | 0.009235 |
186 | CELLULAR TRANSITION METAL ION HOMEOSTASIS | 10 | 77 | 0.0003868 | 0.009675 |
187 | NEURON PROJECTION GUIDANCE | 18 | 205 | 0.0003987 | 0.00992 |
188 | REGULATION OF TRANSPORT | 91 | 1804 | 0.0004009 | 0.009923 |
Num | GO | Overlap | Size | P Value | Adj. P Value |
---|---|---|---|---|---|
1 | ENZYME BINDING | 115 | 1737 | 3.835e-11 | 3.563e-08 |
2 | TRANSCRIPTION FACTOR ACTIVITY RNA POLYMERASE II CORE PROMOTER PROXIMAL REGION SEQUENCE SPECIFIC BINDING | 32 | 328 | 2.647e-07 | 0.000123 |
3 | REGULATORY REGION NUCLEIC ACID BINDING | 56 | 818 | 2.189e-06 | 0.000678 |
4 | RNA POLYMERASE II TRANSCRIPTION FACTOR ACTIVITY SEQUENCE SPECIFIC DNA BINDING | 46 | 629 | 3.271e-06 | 0.0007597 |
5 | MOLECULAR FUNCTION REGULATOR | 80 | 1353 | 4.815e-06 | 0.0008946 |
6 | UBIQUITIN LIKE PROTEIN TRANSFERASE ACTIVITY | 34 | 420 | 7.75e-06 | 0.0012 |
7 | CYTOSKELETAL PROTEIN BINDING | 54 | 819 | 9.885e-06 | 0.001312 |
8 | TRANSCRIPTION FACTOR BINDING | 38 | 524 | 2.81e-05 | 0.003263 |
9 | GUANYL NUCLEOTIDE EXCHANGE FACTOR ACTIVITY | 26 | 303 | 3.369e-05 | 0.003477 |
10 | TRANSCRIPTION FACTOR ACTIVITY DIRECT LIGAND REGULATED SEQUENCE SPECIFIC DNA BINDING | 9 | 48 | 4.17e-05 | 0.003874 |
11 | NUCLEIC ACID BINDING TRANSCRIPTION FACTOR ACTIVITY | 69 | 1199 | 5.289e-05 | 0.004467 |
12 | TRANSCRIPTIONAL ACTIVATOR ACTIVITY RNA POLYMERASE II TRANSCRIPTION REGULATORY REGION SEQUENCE SPECIFIC BINDING | 26 | 315 | 6.47e-05 | 0.004916 |
13 | RAS GUANYL NUCLEOTIDE EXCHANGE FACTOR ACTIVITY | 21 | 228 | 6.879e-05 | 0.004916 |
14 | MAP KINASE KINASE KINASE ACTIVITY | 6 | 22 | 9.052e-05 | 0.006007 |
15 | KINASE ACTIVITY | 51 | 842 | 0.0001525 | 0.008332 |
16 | TRANSCRIPTION FACTOR ACTIVITY PROTEIN BINDING | 39 | 588 | 0.0001505 | 0.008332 |
17 | GTPASE BINDING | 24 | 295 | 0.0001522 | 0.008332 |
18 | E BOX BINDING | 7 | 34 | 0.000162 | 0.008363 |
19 | TRANSCRIPTIONAL ACTIVATOR ACTIVITY RNA POLYMERASE II CORE PROMOTER PROXIMAL REGION SEQUENCE SPECIFIC BINDING | 20 | 226 | 0.0001749 | 0.008553 |
20 | UBIQUITIN LIKE PROTEIN LIGASE BINDING | 22 | 264 | 0.0002016 | 0.009364 |
21 | STEROID HORMONE RECEPTOR ACTIVITY | 9 | 59 | 0.0002206 | 0.009662 |
22 | CALMODULIN BINDING | 17 | 179 | 0.0002288 | 0.009662 |
Num | GO | Overlap | Size | P Value | Adj. P Value |
---|---|---|---|---|---|
1 | CYTOSKELETON | 113 | 1967 | 1.756e-07 | 0.0001026 |
2 | CELL LEADING EDGE | 33 | 350 | 3.791e-07 | 0.0001107 |
3 | MEMBRANE REGION | 68 | 1134 | 1.666e-05 | 0.003243 |
4 | AXON | 31 | 418 | 0.0001007 | 0.009579 |
5 | CELL PROJECTION | 93 | 1786 | 0.0001148 | 0.009579 |
6 | CUL3 RING UBIQUITIN LIGASE COMPLEX | 10 | 64 | 8.081e-05 | 0.009579 |
7 | AXON PART | 20 | 219 | 0.0001142 | 0.009579 |
Num | Pathway | Pathview | Overlap | Size | P Value | Adj. P Value |
---|---|---|---|---|---|---|
1 | Focal_adhesion_hsa04510 | 21 | 199 | 8.967e-06 | 0.0004663 | |
2 | MAPK_signaling_pathway_hsa04010 | 25 | 295 | 5.813e-05 | 0.001511 | |
3 | TNF_signaling_pathway_hsa04668 | 13 | 108 | 0.0001197 | 0.002075 | |
4 | PI3K_Akt_signaling_pathway_hsa04151 | 27 | 352 | 0.000161 | 0.002093 | |
5 | HIF_1_signaling_pathway_hsa04066 | 12 | 100 | 0.000223 | 0.002093 | |
6 | FoxO_signaling_pathway_hsa04068 | 14 | 132 | 0.0002585 | 0.002093 | |
7 | Gap_junction_hsa04540 | 11 | 88 | 0.0002818 | 0.002093 | |
8 | Signaling_pathways_regulating_pluripotency_of_stem_cells_hsa04550 | 14 | 139 | 0.0004406 | 0.002693 | |
9 | Hippo_signaling_pathway_multiple_species_hsa04392 | 6 | 29 | 0.0004661 | 0.002693 | |
10 | p53_signaling_pathway_hsa04115 | 9 | 68 | 0.0006513 | 0.003233 | |
11 | Jak_STAT_signaling_pathway_hsa04630 | 15 | 162 | 0.0006839 | 0.003233 | |
12 | Hippo_signaling_pathway_hsa04390 | 14 | 154 | 0.001218 | 0.005276 | |
13 | Rap1_signaling_pathway_hsa04015 | 16 | 206 | 0.002918 | 0.01065 | |
14 | TGF_beta_signaling_pathway_hsa04350 | 9 | 84 | 0.002946 | 0.01065 | |
15 | Tight_junction_hsa04530 | 14 | 170 | 0.003074 | 0.01065 | |
16 | Oocyte_meiosis_hsa04114 | 11 | 124 | 0.004728 | 0.01537 | |
17 | Phospholipase_D_signaling_pathway_hsa04072 | 12 | 146 | 0.005985 | 0.01831 | |
18 | mTOR_signaling_pathway_hsa04150 | 12 | 151 | 0.007769 | 0.02244 | |
19 | Ras_signaling_pathway_hsa04014 | 16 | 232 | 0.009016 | 0.02451 | |
20 | Sphingolipid_signaling_pathway_hsa04071 | 10 | 118 | 0.009425 | 0.02451 | |
21 | ErbB_signaling_pathway_hsa04012 | 8 | 85 | 0.01066 | 0.02588 | |
22 | AMPK_signaling_pathway_hsa04152 | 10 | 121 | 0.01114 | 0.02588 | |
23 | cAMP_signaling_pathway_hsa04024 | 14 | 198 | 0.01145 | 0.02588 | |
24 | Cellular_senescence_hsa04218 | 12 | 160 | 0.01201 | 0.02601 | |
25 | Adherens_junction_hsa04520 | 7 | 72 | 0.01391 | 0.02893 | |
26 | Calcium_signaling_pathway_hsa04020 | 12 | 182 | 0.02966 | 0.05933 | |
27 | Regulation_of_actin_cytoskeleton_hsa04810 | 13 | 208 | 0.03531 | 0.06801 | |
28 | VEGF_signaling_pathway_hsa04370 | 5 | 59 | 0.05818 | 0.1081 | |
29 | cGMP_PKG_signaling_pathway_hsa04022 | 10 | 163 | 0.06614 | 0.1186 | |
30 | ECM_receptor_interaction_hsa04512 | 6 | 82 | 0.0716 | 0.1211 | |
31 | Lysosome_hsa04142 | 8 | 123 | 0.07222 | 0.1211 | |
32 | Hedgehog_signaling_pathway_hsa04340 | 4 | 47 | 0.08509 | 0.1361 | |
33 | Autophagy_animal_hsa04140 | 8 | 128 | 0.08637 | 0.1361 | |
34 | Endocytosis_hsa04144 | 13 | 244 | 0.0966 | 0.1477 | |
35 | Apoptosis_hsa04210 | 8 | 138 | 0.1192 | 0.1768 | |
36 | NF_kappa_B_signaling_pathway_hsa04064 | 6 | 95 | 0.1224 | 0.1768 | |
37 | Wnt_signaling_pathway_hsa04310 | 8 | 146 | 0.1495 | 0.2101 | |
38 | Cytokine_cytokine_receptor_interaction_hsa04060 | 13 | 270 | 0.1668 | 0.2254 | |
39 | Ferroptosis_hsa04216 | 3 | 40 | 0.1691 | 0.2254 | |
40 | Mitophagy_animal_hsa04137 | 4 | 65 | 0.2 | 0.26 | |
41 | Cell_adhesion_molecules_.CAMs._hsa04514 | 7 | 145 | 0.2579 | 0.3272 | |
42 | Phosphatidylinositol_signaling_system_hsa04070 | 5 | 99 | 0.2763 | 0.3377 | |
43 | Cell_cycle_hsa04110 | 6 | 124 | 0.2793 | 0.3377 | |
44 | Apoptosis_multiple_species_hsa04215 | 2 | 33 | 0.3288 | 0.3886 | |
45 | Necroptosis_hsa04217 | 7 | 164 | 0.3658 | 0.4227 | |
46 | Notch_signaling_pathway_hsa04330 | 2 | 48 | 0.513 | 0.5799 | |
47 | Apelin_signaling_pathway_hsa04371 | 5 | 137 | 0.5398 | 0.5973 | |
48 | Phagosome_hsa04145 | 5 | 152 | 0.6322 | 0.6849 | |
49 | Peroxisome_hsa04146 | 2 | 83 | 0.7994 | 0.8483 | |
50 | Neuroactive_ligand_receptor_interaction_hsa04080 | 5 | 278 | 0.9714 | 1 |